Who owns Nurix Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of NRIX from SEC Form 13F filings across 211 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 211 institutions disclosed 117.2M shares of Nurix Therapeutics, Inc. worth $2.84B — about 105.5% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
211
13F holders
$2.84B
value, 2026 filers
105.5%
of shares outstanding (117.2M sh)
45
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of NRIX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8.8M | $212.8M | 0.0% | 7.9% | -1.7% |
| 2 | Vestal Point Capital, LP | 8.1M | $195.3M | 4.6% | 7.2% | +23.8% |
| 3 | Deep Track Capital, LP | 7.7M | $187.7M | 2.7% | 7% | +21.9% |
| 4 | Rubric Capital Management LP | 7.2M | $175.3M | 1.6% | 6.5% | +192.2% |
| 5 | FMR LLC | 5.5M | $133.1M | 0.0% | 4.9% | -1.0% |
| 6 | PRICE T ROWE ASSOCIATES INC /MD/ | 5.4M | $131.9M | 0.0% | 4.9% | +65.2% |
| 7 | MORGAN STANLEY | 4.8M | $115.5M | 0.0% | 4.3% | -3.4% |
| 8 | STATE STREET CORP | 4.7M | $113.5M | 0.0% | 4.2% | -9.0% |
| 9 | BAKER BROS. ADVISORS LP | 4.7M | $113.0M | 0.6% | 4.2% | 0.0% |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 4.5M | $109.1M | 0.0% | 4% | +1.5% |
| 11 | PERCEPTIVE ADVISORS LLC | 4.3M | $104.8M | 1.6% | 3.9% | +16.4% |
| 12 | Redmile Group, LLC | 4.1M | $98.8M | 6.6% | 3.7% | -47.3% |
| 13 | GENERAL ATLANTIC, L.P. | 3.0M | $73.6M | 2.5% | 2.7% | -26.1% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 2.5M | $61.6M | 0.0% | 2.3% | +0.7% |
| 15 | Pictet Asset Management Holding SA | 2.4M | $57.0M | 0.1% | 2.1% | -13.8% |
| 16 | ARK Investment Management LLC | 1.8M | $43.5M | 0.3% | 1.6% | +4.2% |
| 17 | Capital World Investors | 1.8M | $43.4M | 0.0% | 1.6% | +100.1% |
| 18 | Trails Edge Capital Partners, LP | 1.6M | $38.2M | 6.1% | 1.4% | -9.8% |
| 19 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.5M | $36.0M | 0.0% | 1.3% | +34.5% |
| 20 | CITADEL ADVISORS LLC | 1.5M | $35.8M | 0.0% | 1.3% | +9.9% |
| 21 | Soleus Capital Management, L.P. | 1.5M | $35.5M | 1.2% | 1.3% | +56.2% |
| 22 | DIMENSIONAL FUND ADVISORS LP | 1.4M | $34.7M | 0.0% | 1.3% | +83.3% |
| 23 | EVENTIDE ASSET MANAGEMENT, LLC | 1.3M | $31.5M | 0.4% | 1.2% | 0.0% |
| 24 | BRAIDWELL LP | 1.3M | $31.2M | 1.2% | 1.2% | -26.5% |
| 25 | Kynam Capital Management, LP | 1.2M | $29.0M | 1.6% | 1.1% | 0.0% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.